Tempus AI Inc. (NASDAQ: TEM), a Chicago-based health technology firm, fell to pieces on Wednesday when Spruce Point revealed a shorting position.
Spruce Point gave several reasons for betting against Nasdaq-listed firm, such as account irregularities, and the erosion of ties with clients, like AstraZeneca.
Tempus AI’s shares are on a roll lately. Despite today’s drop, the stock is still up over 40% from its year-to date low, set in early April.
Why does Spruce point have a short position in Tempus AI stocks for 2025?
Spruce point claims that the top executives of this health-tech company, as well as its board, are known for creating disruptive technology firms, which make big promises but fail to deliver.
The short report of the investment company said that investors who cash out too early can make millions but still leave shareholders with low returns.
Tempus AI’s management also misleads investors regarding their artificial intelligence use.
Last year, the company, based in Chicago, Illinois, rebranded itself from “Tempus labs” to “Tempus AI”, to capitalize on AI hype.
The short seller argued that TEM’s AI capabilities are grossly overstated.
TEM shares are overvalued in their current level
Tempus stock should not be purchased by investors this year despite the fact that many recent accusations against the company were ultimately unfounded.
It is the valuation that should be of primary concern. The TEM share price has risen beyond the current value of its fundamentals since April 8.
It has not yet reported a profit, or generated a positive cash flow. This makes its pricing seem excessive compared to the company’s financial performance.
Last year, the Nasdaq-listed company lost $1.58 per share on revenues of $693.4 millions. Analysts had predicted $696.3 millions instead.
Wall Street is bullish about Tempus AI Inc
Wall Street is still bullish about Tempus AI for the rest of this year, despite Spruce Point’s report.
The average target price for the AI-enabled healthcare firm is nearly $65. This indicates a potential gain of over 20% on current levels.
The company’s earnings in Q1 could have been a factor. TEM lost 24 cents per share in the first quarter.
The consensus was 248 million dollars and 26 cents per share.
It’s worth noting that Cathie, an influential investor is also long on this AI stock.
Her investment company purchased 400,000 shares in March of Tempus AI, spread across its two flagship ETFs.
The ICD first published this post Tempus AI Stock was not worth buying even with the short report. Find out why.
This site is for entertainment only. Click here to read more
